» Articles » PMID: 28237646

Recurrence-associated Genes in Papillary Thyroid Cancer: An Analysis of Data from The Cancer Genome Atlas

Overview
Journal Surgery
Specialty General Surgery
Date 2017 Feb 27
PMID 28237646
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recurrence of papillary thyroid cancer is not uncommon, but incorporating clinicopathologic parameters to predict recurrence is suboptimal. The aim of this study was to identify systemically recurrence-associated genes using The Cancer Genome Atlas RNA sequencing database.

Methods: A total of 504 patients with transcriptome sequencing data of the primary neoplasm were included in this study. High and low levels of expression of each gene were defined by median splits. Differences in recurrence-free survival were compared using Kaplan-Meier curves and log-rank tests. Recurrence-associated genes were subjected to functional enrichment analyses with Kyoto Encyclopedia of Genes and Genomes annotation databases and Ingenuity Pathway Analysis.

Results: We found that 1,807 genes were associated with recurrence-free survival. There were 676 genes of which high expression was associated with a greater risk of recurrence. These genes were enriched in pathways involved in cell cycle regulation and DNA repair. Among 1,131 genes of which low expression was associated with recurrence, Kyoto Encyclopedia of Genes and Genomes-annotated functions were metabolism, calcium signaling, glycan biosynthesis, and the Notch signaling pathway. Canonical pathways identified by Ingenuity Pathway Analysis included RXR function, nitric oxide signaling, interleukin-8 signaling, and nutrient sensing. In addition, low expression of the majority of thyroid differentiation genes was associated with a significantly less recurrence-free survival.

Conclusion: Upregulation of cell cycle-regulating and DNA repair genes appears to have a negative impact on recurrence-free survival in patients with papillary thyroid cancer. Furthermore, recurrence is associated with thyroid dedifferentiation.

Citing Articles

Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.

Qu N, Chen D, Ma B, Zhang L, Wang Q, Wang Y Nat Commun. 2024; 15(1):3175.

PMID: 38609408 PMC: 11014849. DOI: 10.1038/s41467-024-47581-1.


Unraveling the role of the mitochondrial one-carbon pathway in undifferentiated thyroid cancer by multi-omics analyses.

Lee S, Park S, Yi S, Choi N, Lim M, Chang J Nat Commun. 2024; 15(1):1163.

PMID: 38331894 PMC: 10853200. DOI: 10.1038/s41467-024-45366-0.


Upregulation of dendrocyte-expressed seven transmembrane protein is associated with unfavorable outcomes in differentiated thyroid cancer.

Lee J, Hsu Y, Huang W, Cheng S Endocrine. 2023; 81(3):513-520.

PMID: 37058220 DOI: 10.1007/s12020-023-03364-0.


Latency Trend Analysis as a Guide to Screening Malignancy Survivors for Second Primary Thyroid Cancer.

Hussein M, Mueller L, Issa P, Haidari M, Trinh L, Toraih E Biomedicines. 2022; 10(8).

PMID: 36009531 PMC: 9406053. DOI: 10.3390/biomedicines10081984.


Propensity Score-Matched Analysis to Identify Pathways Associated with Loss of Sodium Iodide Symporter in Papillary Thyroid Cancer.

Lee F, Kuo C, Tsai C, Cheng S Curr Issues Mol Biol. 2022; 44(4):1488-1496.

PMID: 35723359 PMC: 9164071. DOI: 10.3390/cimb44040101.